The incidence of the non-Hodgkin's lymphomas appears to be rising in the developed world, and is now approximately 6/ 100 000 in the European community and 10/100 000 in the US (Esteve et al., 1993) . Approximately one-third of patients with histologically aggressive disease can be cured by combination chemotherapy, and this has been seen as one of the major successes for cancer therapy in the last 20 years. McKelvey et al. (1976) reported on the successful use of a combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), and this has since been considered as standard therapy. During the 1980s second-and thirdgeneration regimens were introduced, which in non-randomised studies from single centres suggested improved outcome (Mathe et al., 1974; Fisher et al., 1983 Fisher et al., , 1984 Shipp et al., 1986) . These regimens include a larger number of agents and a higher relative dose intensity (Hryniuk, 1988) .
A particularly high complete remission (CR) rate (84%) and 3 year overall survival (76%) was reported with the MACOP-B regimen, which used six drugs given in alternating weekly cycles of myelosuppressive and non-myelosuppressive agents for 11 weeks (Klimo and Connors, 1985) . This regimen was developed in accord with the model of tumour resistance proposed by Goldie et al. (1982) .
In an attempt to improve the efficacy and reduce the toxicity of MACOP-B, Sweetenham et al. (1991) developed the PACEBOM regimen, which incorporates etoposide, which has proven anti-lymphoma activity (Cecil et al., 1978) , and reduced the doses of methotrexate and corticosteroids, which were thought to be the major source of toxicity with the MACOP-B regimen. The PACEBOM regimen was reasonably well tolerated, and in a small study of 61 patients with advanced disease the average relative dose intensity delivered was 87% of the planned dose (Sweetenham et al., 1991 (Table I) . A minimum of six cycles was given with two courses beyond the attainment of CR. The PACEBOM regimen was a seven-drug regimen given in weekly alternating cycles of potentially non-crossresistant drugs over 11 weeks, as previously described (Sweetenham et al., 1991) (Table I ). The hypothetical relative intensity compared with a standardised nine-drug regimen (De Vita, 1987 ) was calculated as previously described (Hryniuk, 1988) It should be noted that in the original description of the PACEBOM protocol (Sweetenham et al., 1991 ) the lower neutrophil limit at which the drugs were delayed was 0.1 x 109 1-' rather than 0.3 x I09 1-' used in this study.
In both arms of the study the doxorubicin dose was reduced to 50% if the bilirubin was raised between 35 and 50 mmol I`and reduced to 25% if the bilirubin was greater than 50 mmol`'.
Response evaluation All patients were assessed for response at 3 months after the start of therapy. This was to include all previously abnormal investigations. Further assessment was carried out at the end of therapy and 3 months later. All patients were then continuously followed up (one lost), and the frequency of repeat investigations varied according to individual centre practice.
Complete remission (CR) was defined as the complete disappearance of all clinical disease manifestations and the reversal of all previously abnormal investigations maintained for at least 3 months after the completion of therapy. Partial remission (PR) was defined as the reduction of at least 50% in the sums of the products of biperpendicular diameters of known disease by the end of therapy. 'No response' (NR) was defined as any response less than PR. Patients not attaining a CR at the end of therapy or progressing during therapy were given further treatment at the physician's discretion.
Statistical methods
The trial was planned to accrue at least 375 patients. This gave a 90% chance of detecting an overall improvement in survival rate of 15% at the 5% significance level assuming the 5 year survival in the CHOP arm was 45% (Freedman, 1982) , which is in line with historical data.
Complete remission rates were compared by the use of a chi-square test, with Yates' correction (Yates, 1934) . Survival curves were calculated by the life-table method, and statistical comparison of curves performed by the log-rank test as described by Peto et al. (1971) . Adjustment of plot for imbalances in the frequency distribution of variables in the (Table IV) .
Protocol violations
Eleven patients in the CHOP arm (5%) had major protocol violations. These included unscheduled chemotherapy in four patients (one given PACEBOM) and consolidation radiotherapy (RT) in first CR in seven patients. In the PACEBOM arm there were 11 major protocol violations (5%); three patients were given unscheduled chemotherapy (two given CHOP) and eight were given consolidation RT in first CR. analysis. and was not therefore planned at the initiation of the trial. Caution must therefore be exercised in the interpretation of these results given the number of possible subgroup comparisons and the fact that these were not specified beforehand (Byse. 1989 (Freedman. 1982) . Thirdly. it is possible that the advantage seen with PACEBOM is because PACEBOM is a superior therapy to CHOP, and by inference to other third-generation regimens. The PACEBOM regimen is a weekly alternating non-crossresistant regimen with a relative dose intensity of 0.54 which is very similar to MACOP-B (0.51). The major difference is the inclusion of etoposide in PACEBOM, although the significance of this is not known. It would be of interest to know the received dose intensities in this trial but these data are not available.
As previously stated. it was not possible to analyse this trial fully in terms of the international index as LDH levels were not recorded in many patients. It was possible. however. in the patients under 60 years of age to designate 231 patients as either high risk or low risk on the index. This confirmed that high-risk patients, so defined, have a lower CR rate and overall survival. but it is noteworthy that there was little difference in the relapse rate once a CR was attained. This emphasises that future attempts to improve outcome in poorrisk patients should address better initial therapy rather than focus on consolidation therapy in patients who have already attained a CR.
In conclusion, this trial has raised the possibility that PACEBOM may be a superior therapy to CHOP in poor prognosis patients with histologically aggressive non-Hodgkin's lymphoma. particularly in those patients with stage IV disease. although caution must be exercised with subgroup analyses.
